Literature DB >> 21913342

Role of phacoemulsification in angle closure glaucoma.

Sasan Moghimi1, Shan Lin.   

Abstract

Cataract or clear Lens extraction has been suggested as a treatment option for different spectrums of primary angle closure diseases. It might reduce the risk of progression of angle closure and/or glaucoma by helping to open the angle and control the intraocular pressure (IOP). Conventionally, medically uncontrolled primary angle closure glaucoma was treated with trabeculectomy or phacotrabeculectomy and acute primary angle closure was treated with laser peripheral iridotomy. However, recent randomized controlled trials have demonstrated greater promise of phacoemulsification cataract surgery alone for control of the IOP. In this report we review the current literature to evaluate the impact of cataract surgery upon preventing and controlling primary angle closure diseases.

Entities:  

Mesh:

Year:  2011        PMID: 21913342     DOI: 10.3969/j.issn.1000-4432.2011.03.001

Source DB:  PubMed          Journal:  Eye Sci


  4 in total

1.  Comparison of phacotrabeculectomy and sequential surgery in the treatment of chronic angle-closure glaucoma coexisted with cataract.

Authors:  Hai-Jun Li; Jie Xuan; Xiao-Min Zhu; Lin Xie
Journal:  Int J Ophthalmol       Date:  2016-05-18       Impact factor: 1.779

2.  Cataract surgery in eyes with filtered primary angle closure glaucoma.

Authors:  Sasan Moghimi; Golshan Latifi; Heydar Amini; Masood Mohammadi; Ghasem Fakhraie; Yadollah Eslami; Nariman Nassiri; Joseph Caprioli
Journal:  J Ophthalmic Vis Res       Date:  2013-01

3.  Phacoemulsification: an alternative for prophylaxis of a glaucomatous crisis.

Authors:  Ricardo Alexandre Stock; Mariéli Wobeto Röhrig; Camila Duranti Mezzomo; Elcio Luiz Bonamigo
Journal:  Clin Ophthalmol       Date:  2019-09-05

4.  Classification of primary angle closure spectrum with hierarchical cluster analysis.

Authors:  Sasan Moghimi; Ali Torkashvand; Massood Mohammadi; Mehdi Yaseri; Luke J Saunders; Shan C Lin; Robert N Weinreb
Journal:  PLoS One       Date:  2018-07-23       Impact factor: 3.240

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.